在产后心脏发育过程中,PIDDosome控制心肌细胞多化
1Biocenter, Institute for Developmental Immunology, Medical University of Innsbruck, Innsbruck, Austria. macileo@hotmail.com.
Cell death and differentiation
|January 12, 2026
概括
在发育过程中,PIDDosome复合体限制了心脏细胞中的多体化. 失去PIDDosome功能会增加细胞化,这可能会影响老年小鼠的心脏功能.
科学领域:
- 心脏病学 心脏病学
- 细胞生物学 细胞生物学
- 发展生物学 发展生物学
背景情况:
- 成年哺乳动物心肌细胞 (CMs) 是异粒体后和多倍体的.
- 了解CM细胞周期的退出和多重积分对于心脏再生疗法至关重要.
研究的目的:
- 为了研究PIDDosome复合体在调节心肌细胞 (CM) 聚化在产后心脏发育过程中的作用.
- 确定PIDD对心脏结构和功能的PIDD所介导的多化控制的影响.
主要方法:
- 用DNA内容分析来评估心肌细胞化.
- 研究涉及ANKRD26和PIDD1.1的PIDD基因组激活机制.
- 使用核RNA测序和遗传删除实验.
- 在小鼠中评估心脏结构和功能与改变的PIDDosome活动.
主要成果:
- 细胞自主性PIDD 细胞损失导致CM核和细胞 ploidy 的增加.
- 皮尔多多化控制发生在出生后的第7天和P14之间.
- 皮德基因组激活需要ANKRD26并将PIDD1定位为母中心.
- 由于PIDD所致的增多皮质损失会影响老年小鼠的心脏功能.
- PIDDosome 独立于 p53 限制了 CM 聚化,但需要 p21/Cdkn1a 诱导.
结论:
- PIDDosome复合体在实施一个CM特异的分化程序中发挥着关键作用,该程序在产后心脏发育过程中限制了多化.
- 基因组介导的CM多聚化控制对于维持心脏功能至关重要,特别是在衰老中.
- 这些发现为限制多倍体CM增殖提供了新的见解,并对心脏再生疗法产生了影响.
相关概念视频
Development of the Heart
The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart tube by...
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart tube by...
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...


